Abstract:The purpose of this study is to determine the factors related to anxiety and depression in patients with retinitis pigmentosa (RP). The status of anxiety and depression was determined in RP patients with the Hospital Anxiety and Depression Scale (HADS) questionnaire which consisted of subscales for HADS-anxiety (HADS-A) and HADS-depression (HADS-D). The vision-specific quality of life (VSQOL) was assessed with the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ25). The correlations between the… Show more
“…This finding alone, although controversial among previous studies, has been reported in the past. [18][19][20][21][22][23][24] To further understand the implications of this difference, further analysis was completed to calculate the effect size or magnitude of this difference. This value is presented in terms of increased odds of patients with RP to have a diagnosis of anxiety by 4.9-fold, depression by 5.6-fold, and both anxiety and depression by 4.1-fold when compared with those without RP.…”
Section: Discussionmentioning
confidence: 99%
“…Possibly because of variations in the base study populations, the presence of increased risk, variance in the reported rate, and presence of influencing patient characteristics are conflicting. [18][19][20][21][22][23][24] Similarly, investigations on the relationship between RP and anxiety have also produced conflicting reports on the association. 19,20 Although it is important to identify the presence or absence of an association between RP with anxiety and depression, the magnitude or effect size of the difference is equally significant.…”
Purpose: Retinitis pigmentosa (RP) is a chronic progressive disease with no curative treatments. Understanding the variables involved with improving patients’ quality of life is important in managing this population. The literature investigating the relationship of anxiety and depression with RP relies on the analysis of smaller subset populations of patients with RP, and no study has quantified the effect size of the potential association. This study aims to elucidate and quantify the association between RP, anxiety, and depression. Methods: A retrospective case-control study was conducted of 6 093 833 medical records within the University of North Carolina Hospital and outpatient clinic system from July 1, 2004, to August 30, 2019. Patients with a diagnosis of RP, anxiety, and depression were identified within the Carolina Data Warehouse for Health by International Classification of Diseases, Ninth and Tenth Revision codes. Results: From the base population of 6 093 833 patients' medical records, 690 patients were diagnosed with RP, 253 065 with anxiety, and 232 541 with depression. Patients with RP have an odds ratio, adjusted for sex and age, of 4.915 (95% CI, 4.035-5.987) for having comorbid anxiety, 5.609 (95% CI, 4.622-6.807) for comorbid depression, and 4.130 (95% CI, 3.187-5.353) for comorbid anxiety and depression. Conclusions: Patients with RP have a higher prevalence of anxiety and depression, with increased odds of approximately 5 to 6 times for also carrying a diagnosis of anxiety or depression and about 4 times for carrying diagnoses of anxiety and depression compared with the general population.
“…This finding alone, although controversial among previous studies, has been reported in the past. [18][19][20][21][22][23][24] To further understand the implications of this difference, further analysis was completed to calculate the effect size or magnitude of this difference. This value is presented in terms of increased odds of patients with RP to have a diagnosis of anxiety by 4.9-fold, depression by 5.6-fold, and both anxiety and depression by 4.1-fold when compared with those without RP.…”
Section: Discussionmentioning
confidence: 99%
“…Possibly because of variations in the base study populations, the presence of increased risk, variance in the reported rate, and presence of influencing patient characteristics are conflicting. [18][19][20][21][22][23][24] Similarly, investigations on the relationship between RP and anxiety have also produced conflicting reports on the association. 19,20 Although it is important to identify the presence or absence of an association between RP with anxiety and depression, the magnitude or effect size of the difference is equally significant.…”
Purpose: Retinitis pigmentosa (RP) is a chronic progressive disease with no curative treatments. Understanding the variables involved with improving patients’ quality of life is important in managing this population. The literature investigating the relationship of anxiety and depression with RP relies on the analysis of smaller subset populations of patients with RP, and no study has quantified the effect size of the potential association. This study aims to elucidate and quantify the association between RP, anxiety, and depression. Methods: A retrospective case-control study was conducted of 6 093 833 medical records within the University of North Carolina Hospital and outpatient clinic system from July 1, 2004, to August 30, 2019. Patients with a diagnosis of RP, anxiety, and depression were identified within the Carolina Data Warehouse for Health by International Classification of Diseases, Ninth and Tenth Revision codes. Results: From the base population of 6 093 833 patients' medical records, 690 patients were diagnosed with RP, 253 065 with anxiety, and 232 541 with depression. Patients with RP have an odds ratio, adjusted for sex and age, of 4.915 (95% CI, 4.035-5.987) for having comorbid anxiety, 5.609 (95% CI, 4.622-6.807) for comorbid depression, and 4.130 (95% CI, 3.187-5.353) for comorbid anxiety and depression. Conclusions: Patients with RP have a higher prevalence of anxiety and depression, with increased odds of approximately 5 to 6 times for also carrying a diagnosis of anxiety or depression and about 4 times for carrying diagnoses of anxiety and depression compared with the general population.
“…Zhou et al found that worse self-reported visual function assessed by Glaucoma Quality of Life-15 questionnaire (GQL-15) was consistently correlated with decreased anxiety and depression in glaucoma patients [2]. In retinitis pigmentosa patients, the degree of anxiety was signi cantly correlated with the general health and role di culties of the NEI VFQ-25 dimensions but not with any objective visual functions, such as BCVA of better-and worse-seeing eyes [19]. With regard to depression, our results were consistent with several previous studies.…”
Background: To investigate anxiety and depression in glaucoma patients and its correlations with vision-related quality of life (VR-QoL) and objective visual function indices.Methods: In this cross-sectional study, the Hospital Anxiety and Depression Scale (HADS) and the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) questionnaires were administered to 446 Chinese glaucoma patients to assess their psychological disorders, namely anxiety and depression, and VR-QoL, respectively. Socio-demographic and clinical data were collected at the same time. Multivariate linear regression analysis was carried out to investigate the associations between VR-QoL, visual function indices and psychological disorders. Standardized partial regression analysis was used to identify the variable mostly indicative in evaluating psychological burdens. Results: The prevalence of anxiety and depression in Chinese glaucoma patients was 12.11% and 25.78%, respectively. Most of the subscales and the composite score of NEI VFQ-25 were negatively associated with each of anxiety and depression after adjusting for socio-demographic and clinical variables. For visual function indices, only the best corrected visual acuity of both eyes was correlated with anxiety after adjustment. Standardized partial regression analysis further showed VR-QoL but not the objective visual function indices mostly relevant to psychological disturbances. Conclusions: Anxiety and depression were common in Chinese glaucoma patients. Self-reported VR-QoL was beneficial in assessing glaucoma patients’ psychological disorders, while objective visual function indices provide little hint on it.
“…Reading a book at home could be more efficiently supported by a text-to-sound or -voice application on a personal computer. Visual function impairment can cause vision-related impairment of QOL 24 , and obtaining a visual field with a view greater than 20 degrees may be useful for walking 25 . The current device that improved the visual field to almost 20 degrees would, at least in part, have a clinically relevant effect.…”
Visual field defects interfere with free actions and influence the quality of life of patients with retinitis pigmentosa; the prevalence of this disease is increasing in aging societies. Patients with progressive disease may require visual aids; however, no such devices are currently available. We utilized a retinal projection eyewear system, QD laser eyewear, which includes a projector inside the spectacle frame, to draw the image taken by a connected portable camera with a wide field lens. The images are projected onto the retina using a Maxwellian view optical system, which is not influenced by refractive error or the amount of incident light. Goldmann perimetry and figure recognition tests with the QD laser eyewear showed increased visual field areas and angles, and shortened the time for recognition of the number of figures in a sheet, in a limited visual field model that we developed by using a pin-hole system to simulate the tunnel vision of retinitis pigmentosa in 19 healthy adults. The device supported the quality of vision. Additionally, the visual field defect model used in healthy adults was useful for validating the device in the development stage of the study, to clarify both advantages and future goals for improving the device.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.